nach oben

Erschienen in:

01.08.2014 | Original Paper

Protein overexpression of CIRP and TLR4 in oral squamous cell carcinoma: an immunohistochemical and clinical correlation analysis

verfasst von: Wen Hao Ren, Lin Mei Zhang, Huai Qin Liu, Ling Gao, Cheng Chen, Cui Qiang, Xiao Long Wang, Chang Yang Liu, Shao Ming Li, Chen Huang, Hong Qi, Ke Qian Zhi

Erschienen in: Medical Oncology | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Oral squamous cell carcinoma (OSCC) is the most common head and neck malignancy. Here, we evaluated the expression of cold-inducible RNA-binding protein (CIRP) and toll-like receptors 4 (TLR4) in OSCC tissues with immunohistochemistry. Using biostatistical methods designed to assess the impact of the expression of CIRP and TLR4 on the prognosis of patients with OSCC and relate that expression to the clinicopathological characteristics of these patients. For the first time, we demonstrated that the expression of CIRP and TLR4 was increased in OSCC and that high levels of CIRP or TLR4 expression were associated with a short survival rate. In addition, we were surprised to find that the levels of expression of CIRP and TLR4 were very similar. The goal of this study was to evaluate whether these two genes may provide clues as to the regulatory mechanisms of OSCC, serve as prognostic markers and establish a new direction for further studies of these biological mechanisms.

Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin. 1996;46(1):5–27.PubMedCrossRef

Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M, et al. SEER cancer statistics review, 1975–2005. Bethesda: National Cancer Institute; 2008. p. 1975–2005.

Chen R, Alvero AB, Silasi DA, Mor G. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol. 2007;57(2):93–107.PubMedCrossRef

Qiang X, Yang W-L, Wu R, Zhou M, Jacob A, Dong W, et al. Cold-inducible RNA-binding protein (CIRP) triggers inflammatory responses in hemorrhagic shock and sepsis. Nat Med. 2013;19(11):1489–95.

Nishiyama H, Itoh K, Kaneko Y, Kishishita M, Yoshida O, Fujita J. A glycine-rich RNA-binding protein mediating cold-inducible suppression of mammalian cell growth. J Cell Biol. 1997;137(4):899–908.PubMedCentralPubMedCrossRef

Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995;9(10):1149–63.PubMedCrossRef

Sakurai T, Itoh K, Higashitsuji H, Nonoguchi K, Liu Y, Watanabe H, et al. Cirp protects against tumor necrosis factor-α-induced apoptosis via activation of extracellular signal-regulated kinase. Biochim Biophys Acta (BBA)-Mol Cell Res. 2006;1763(3):290–5.CrossRef

Guo X, Wu Y, Hartley RS. Cold-inducible RNA-binding protein contributes to human antigen R and cyclin E1 deregulation in breast cancer. Mol Carcinog. 2010;49(2):130–40.PubMedCentralPubMed

Nishiyama H, Higashitsuji H, Yokoi H, Itoh K, Danno S, Matsuda T, et al. Cloning and characterization of human CIRP (cold-inducible RNA-binding protein) cDNA and chromosomal assignment of the gene. Gene. 1997;204(1):115–20.PubMedCrossRef

10.

Nishiyama H, Danno S, Kaneko Y, Itoh K, Yokoi H, Fukumoto M, et al. Decreased expression of cold-inducible RNA-binding protein (CIRP) in male germ cells at elevated temperature. Am J Pathol. 1998;152(1):289.PubMedCentralPubMed

11.

Nishiyama H, Xue J-H, Sato T, Fukuyama H, Mizuno N, Houtani T, et al. Diurnal change of the cold-inducible RNA-binding protein (Cirp) expression in mouse brain. Biochem Biophys Res Commun. 1998;245(2):534–8.PubMedCrossRef

12.

Xue J-H, Nonoguchi K, Fukumoto M, Sato T, Nishiyama H, Higashitsuji H, et al. Effects of ischemia and H₂O₂ on the cold stress protein CIRP expression in rat neuronal cells. Free Radic Biol Med. 1999;27(11):1238–44.PubMedCrossRef

13.

Sheikh MS, Carrier F, Papathanasiou MA, Hollander MC, Zhan Q, Yu K, et al. Identification of several human homologs of hamster DNA damage-inducible transcripts cloning and characterization of a novel uv-inducible cDNA that codes for a putative RNA-binding protein. J Biol Chem. 1997;272(42):26720–6.PubMedCrossRef

14.

Wellmann S, Bührer C, Moderegger E, Zelmer A, Kirschner R, Koehne P, et al. Oxygen-regulated expression of the RNA-binding proteins RBM3 and CIRP by a HIF-1-independent mechanism. J Cell Sci. 2004;117(9):1785–94.PubMedCrossRef

15.

Park JS, Svetkauskaite D, He Q, Kim J-Y, Strassheim D, Ishizaka A, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004;279(9):7370–7.PubMedCrossRef

16.

Ohashi K, Burkart V, Flohé S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. 2000;164(2):558–61.PubMedCrossRef

17.

Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med. 2002;195(1):99–111.PubMedCentralPubMedCrossRef

18.

Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra domain A of fibronectin activates toll-like receptor 4. J Biol Chem. 2001;276(13):10229–33.PubMedCrossRef

19.

Benhamou Y, Favre J, Musette P, Renet S, Thuillez C, Richard V, et al. Toll-like receptors 4 contribute to endothelial injury and inflammation in hemorrhagic shock in mice. Crit Care Med. 2009;37(5):1724–8.PubMedCrossRef

20.

Wittebole X, Castanares-Zapatero D, Laterre PF. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm. 2010. doi:10.1155/2010/568396.

21.

22.

Zeng Y, Kulkarni P, Inoue T, Getzenberg RH. Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity. J Cell Biochem. 2009;107(1):179–88. doi:10.1002/jcb.22114.PubMedCrossRef

23.

Hamid AA, Mandai M, Fujita J, Nanbu K, Kariya M, Kusakari T, et al. Expression of cold-inducible RNA-binding protein in the normal endometrium, endometrial hyperplasia, and endometrial carcinoma. Int J Gynecol Pathol. 2003;22(3):240–7. doi:10.1097/01.pgp.0000070851.25718.ec.PubMedCrossRef

24.

Artero-Castro A, Callejas FB, Castellvi J, Kondoh H, Carnero A, Fernandez-Marcos PJ, et al. Cold-inducible RNA-binding protein bypasses replicative senescence in primary cells through extracellular signal-regulated kinase 1 and 2 activation. Mol Cell Biol. 2009;29(7):1855–68. doi:10.1128/mcb.01386-08.PubMedCentralPubMedCrossRef

25.

He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007;44(11):2850–9. doi:10.1016/j.molimm.2007.01.022.PubMedCrossRef

26.

Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66(7):3859–68. doi:10.1158/0008-5472.can-05-3948.PubMedCrossRef

27.

Molteni M, Marabella D, Orlandi C, Rossetti C. Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Lett. 2006;235(1):75–83. doi:10.1016/j.canlet.2005.04.006.PubMedCrossRef

28.

Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, et al. Triggering of toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 2009;69(7):3105–13. doi:10.1158/0008-5472.can-08-3838.PubMedCentralPubMedCrossRef

29.

Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther. 2007;6(1):299–308.PubMedCrossRef

30.

Sakurai T, Itoh K, Higashitsuji H, Nonoguchi K, Liu Y, Watanabe H, et al. Cirp protects against tumor necrosis factor-alpha-induced apoptosis via activation of extracellular signal-regulated kinase. Biochim Biophys Acta. 2006;1763(3):290–5. doi:10.1016/j.bbamcr.2006.02.007.PubMedCrossRef

31.

Wang AC, Su QB, Wu FX, Zhang XL, Liu PS. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells. Eur J Clin Invest. 2009;39(2):157–64. doi:10.1111/j.1365-2362.2008.02070.x.PubMedCrossRef

Titel: Protein overexpression of CIRP and TLR4 in oral squamous cell carcinoma: an immunohistochemical and clinical correlation analysis
verfasst von: Wen Hao Ren
Lin Mei Zhang
Huai Qin Liu
Ling Gao
Cheng Chen
Cui Qiang
Xiao Long Wang
Chang Yang Liu
Shao Ming Li
Chen Huang
Hong Qi
Ke Qian Zhi
Publikationsdatum: 01.08.2014
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 8/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0120-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Protein overexpression of CIRP and TLR4 in oral squamous cell carcinoma: an immunohistochemical and clinical correlation analysis

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study

Uveitis and T cell lymphoma: a rare but notable relationship

Biomarkers in prostate cancer: new era and prospective

LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy

M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma

Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie